A slow start for self-amplifying mRNA vaccines
A year after the first samRNA vaccine approval, experts say similar vaccines in development are likely to face scientific and regulatory hurdles.
Trilink Thematic saRNA WP
Merck KGaA to advance mRNA vaccine platform with Afrigen
GSK and CureVac restructure mRNA vaccine development deal
Moderna’s mRNA influenza vaccine receives $176m boost
Ascidian and Roche to develop RNA therapies for neurological diseases
BioNTech and CEPI expand deal to boost Africa’s vaccine capabilities
WestGene wins FDA nod to study mRNA vaccine to treat certain cancers
Sanofi signs mRNA vaccine development deal with IDT Australia
